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The effect of thrombolysis in acute myocardial infarction 
on infarct size, left ventricular function, clinical course 
and patient survival was studied in a randomized trial 
comparing thrombolysis (269 patients) with conventional 
treatment (264 control patients). All 533 patients were 
admitted to the coronary care unit within 4 hours after 
the onset of symptoms related to the infarction. Baseline 
characteristics were similar in both groups. Informed 
consent was requested only of patients allocated to 
thrombolysis; no angiography was performed in 35. The 
infarct-related artery was patent in 65 patients and oc•
cluded in 169. Recanalization was achieved in 133 pa•
tients. The median time to angiographic documentation 
of vessel patency was 200 minutes after the onset of 
symptoms. 
The clinical course in the coronary care unit was more 
favorable after thrombolysis. Infarct size, estimated from 
myocardial enzyme release, was 30% lower after throm•
bolysis. In patients admitted within 1 hour after the onset 
of symptoms the reduction of infarct size was 51 %, in 
those admitted between 1 and 2 hours it was 31 % and 
in those admitted later than 2 hours it was 13%. Left 
Myocardial infarction in most patients results from a throm•
botic occlusion of a major coronary artery. Recently, Ren•
trop and other investigators (1-4) have demonstrated that 
rapid recanalization can be achieved by intracoronary in-
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ventricular function measured by radionuclide angiog•
raphy before hospital discharge was better after throm•
bolysis (ejection fraction 48 ± 15 %) than in control 
patients (44 ± 15%). Similar improvement was ob•
served in patients with a first infarct only (thrombolysis 
50 ± 14%, control subjects 46 ± 15%), in patients with 
anterior infarction (thrombolysis 44 ± 16%, control 
subjects 35 ± 14%) and in those with inferior infarction 
(thrombolysis 52 ± 12%, control subjects 49 ± 12%). 
Similar results were obtained by contrast angiography. 
Mortality was lower after thrombolysis. After 28 days 
16 patients allocated to thrombolysis and 31 control pa•
tients had died. One year survival rates were 91 and 
84%, respectively. On the other hand, nonfatal rein•
farction occurred more frequently after thrombolysis (36 
patients) than in control subjects (16 patients). Early 
thrombolysis by intracoronary streptokinase leads to a 
smaller infarct size estimated by enzyme release, pre•
serves left ventricular function at the second week and 
leads to improved 1 year survival. 
(J Am Coli CardioI1986;7:717-28) 
fusion of streptokinase in approximately 80% of patients. 
Because early editorials called for caution (5-7), we initi•
ated in May 1981 a randomized trial to compare a strategy 
aimed at early recanalization by intracoronary administra•
tion of streptokinase with conventional treatment in the coro•
nary care unit. The primary objective was to study the effect 
of the intervention on mortality and morbidity after myo•
cardial infarction. In addition we analyzed the effect of 
attempted thrombolysis on infarct size and left ventricular 
function measured by various methods. 
Because the aim of thrombolysis is rapid restoration of 
blood flow to the jeopardized myocardium to preserve cel-
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Table 1. Distribution of Patients and Results of AngIOgraphy and Thrombolysis in the Four 
Participating Hospitals 
Control Thrombolysis No 
Coronary Patencyt 
Group Group AnglOgraphy* O~O .~O .~. 
Thoraxcenter 118 119 13 24 69 13 
SI. Annadal 62 61 7 17 26 II 
Free University 46 47 9 10 19 9 
Zuiderzlekenhuis 28 33 6 [I 15 I 
Lelden Umversity 10 9 3 4 2 
Total 264 269 35 65 133 36 
Intracoronary 150 152 16 25 88 23 
thrombolysis 
Intravenous and 114 117 19 40 45 13 
mtracoronary 
thrombolysis 
*Angiography was refused by or contraindicated in 35 patients. tThe infarct-related vessel was open and 
remained open in 65 patients (0 ~ 0); recanalization of an occluded vessel was achieved m 133 patients 
(. ~ 0), while the occlusion persisted in 36 patients (. ~ .). Coronary angioplasty was attempted in 46 
patients and succeeded in 44. Note the greater fraction of patients with an open infarct-related vessel at 
angiography after pretreatment with intravenous streptokinase (40 [41 %] of 98 patients) than in patients without 
such treatment (25 [18%] of 136 patients). 
Table 2. Baseline Data in 533 Patients 
Control Thrombolysis 
Group Group 
Number of patients 264 269 
Male 224 (85) 217 (81) 
Age (yr) (mean ± SO) 55 ± 8 56 ± 9 
History 
Angina longer than 4 weeks 74 (28) 69 (26) 
Angina less than 4 weeks 91 (34) 89 (33) 
Previous myocardial infarctIOn 60 (23) 56 (21) 
Previous bypass surgery 8 (3) 5 (2) 
Mamtenance therapy 
None 143 (54) 146 (54) 
Anticoagulant therapy 11(4) 20 (7) 
Beta-blockers 64 (24) 62 (23) 
Calcium antagomsts 31 (12) 31 (12) 
Long-acting mtrates 47 (18) 49 (18) 
Digoxin 6 (2) 8 (3) 
Diuretic drugs 16 (6) 30 (11) 
Therapy before admIssion 
None 134 (51) 133 (49) 
AnalgeSICS 57 (22) 57 (21) 
Antiarrhythmic agents 14 (5) 11 (4) 
Beta-blockers 17 (6) 13 (5) 
Calcium antagonists 24 (9) 28 (10) 
Nitrates 87 (33) 79 (29) 
ResuscitatIOn 5 (2) 7 (3) 
Hemodynamic state 
Heart rate (beats/mm) 74 ± 16 74 ± 17 
Systolic blood pressure (mm Hg) 131 ± 27 131 ::t 30 
Diastolic blood pressure (mm Hg) 84 ± 20 83 ::t 20 
Mild heart failure (no.) 40 (15) 40 (15) 
Acute congestive failure (no.) 2 (1) I (0.5) 
Shock (no.) 9 (3) II (4) 
The actual numbers in each group are presented; percentages are shown 
in parentheses. 
lular integrity and function, time must be a crucial factor 
limiting the salutary effects of thrombolysis. When it be•
came evident that preparation of the catheterization labo•
ratory and introduction of the catheter delayed streptokinase 
infusion by approximately I hour, pretreatment with intra•
venous streptokinase was given to patients who entered the 
trial after December 31, 1983 (4,8-10). The intake was 
completed in March 1985 after entry of 533 patients. Details 
of the design of the study and preliminary data were reported 
in 1982 (11-13). 
Recently, we reported (14) that short-term and 1 year 
survival rates were significantly improved after thrombo•
lysis. The data presented in this final report demonstrate 
that improved survival after early thrombolysis in acute 
myocardial infarction is indeed associated with a reduction 
of infarct size and with preservation of global left ventricular 
function. Furthermore, regional wall motion after throm•
bolysis appeared to be better than in the control group (15). 
Methods 
Patient selection. Patients were eligible for the trial if 
they were admitted to one of the participating coronary care 
units within 4 hours after the onset of chest pain lasting 20 
minutes or more and with electrocardiographic signs com•
patible with myocardial infarction (11-14). ST segment el•
evation of 0.2 mY or greater had to be present in one of 
the precordial leads or 0.1 mY in a limb lead, or both, 
despite treatment with oral or intravenous nitroglycerin or 
nifedipine, or both. In addition, patients were included with 
0.2 mY or greater ST segment depression in precordial 
leads, compatible with posterior wall infarction. 
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Figure 1. Cumulative distributions of the intervals between the 
onset of symptoms and hospital arrival (+- +), arrival in the 
catheterization laboratory (cath. lab) (.-.) and angiographic 
confirmation of a patent infarct-related artery (0-0) when ap•
propriate. 
Exclusion criteria were: 1) age over 70 years; 2) previous 
treatment with streptokinase; 3) bypass surgery of the ves•
sels corresponding to the infarct location; 4) recent trauma 
including traumatic resuscitation; 5) a history of gastroin•
testinal bleeding, ulcer, hematuria or a cerebrovascular ac•
cident within 3 months; 6) pregnancy or menstruation; and 
7) mental confusion that precluded informed consent. 
Treatment protocol. Eligible patients who did not meet 
the exclusion criteria were registered by a central telephone 
answering service. The responsible physician provided ad•
ministrative data including hospital name, patient's initials, 
sex, date of birth and clinical state. The answering service 
then opened the randomization envelope and provided treat•
ment allocation. Informed consent was asked only of pa•
tients allocated to thrombolytic treatment ( 16). Patients who 
refused consent were treated according to the conventional 
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treatment protocol, but were included in the analysis ac•
cording to original treatment allocation. The study protocol 
was approved by the board of the Netherlands Interuniv•
ersity Cardiology Institute. 
In all patients treatment was directed to an "optimal" 
hemodynamic state characterized by sedation, a heart rate 
between 60 and 90 beats/min, systolic blood pressure be•
tween 100 and 140 mm Hg and absence of left ventricular 
failure, including pulmonary capillary wedge pressure less 
than 12 mm Hg when hemodynamic monitoring was used. 
Guidelines for treatment have been described in detail (17) 
and included the use of intraaortic balloon counterpulsation 
for treatment of cardiogenic shock. 
All patients were treated with intravenous heparin fol•
lowed by acenocoumarol (Sintrom) until hospital discharge. 
After discharge anticoagulant agents were continued only 
in patients with ventricular aneurysm, mitral incompetence 
or a large left ventricle with a poor contraction pattern. Beta•
receptor blockers were prescribed in the majority of patients 
starting between 7 and 14 days unless contraindications were 
present. Other therapy was prescribed as needed. 
Thrombolytic therapy. After giving informed consent, 
patients received intravenous nitroglycerin in a dose that 
reduced systolic blood pressure to 100 to 120 mm Hg, as 
well as lidocaine, 2 mg/min, 5,000 U heparin, 250 mg 
acetylsalicylic acid and 100 mg prednisolone (13). Coronary 
angiography was performed with the Judkins technique. If 
the infarct-related artery was occluded, streptokinase was 
given at a rate of 4,000 U/min until all visible clot disap•
peared. Usually a maximum of 250,000 U was given. Sub•
selective catheterization of the occluded coronary branch of 
the left coronary artery or mechanical perforation of the clot 
was employed in a few patients. After completion of strep•
tokinase infusion, complete left and right coronary arteri-
Table 3. Degree of Obstruction* in the Coronary Arteriograms Before and After 
Attempted Reperfusion 
Normal 
Less than 50% 
50 to 90% 
90 to 99% 
Occlusion 
Normal 
Less than 50% 
50 to 90% 
90 to 99% 
OcclUSIOn 
First Angiogram After Streptokinase 
Infarct-Related Artery Without Intravenous Streptokinase 
I 5 
5 40 
19 69 
III 22 
With Prior Intravenous Streptokinase 
2 2 
2 5 
11 28 
25 45 
58 18 
After Streptokmase Plus 
Coronary Angioplastyt 
26 
31 
56 
23 
2 
19 
27 
37 
13 
*Visual analYSIS of the severity of the lesion m the infarct-related vessel, expressed as percent diameter 
stenosis. tPercutaneous transluminal coronary anglOplasty was attempted in 27 patients without and m 19 
patients after pretreatment with intravenous streptokmase 
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Table 4. Clinical Course in Hospital 
Control Thrombolysis 
Group Group p Value 
No. of patIents 264 269 
Hospital mortality (\4 days) 26 14 0.05 
Recurrent mfarctlOn (14 days) 9 12 
Angina pectons 55 57 
Heart fatlure (coronary care unit) 
Mild 55 54 
Severe 12 10 
Shock 24 13 
Dopamme/dobutamme 42 26 0.03 
treatment 
Respiratory support II 6 
Intraaortic balloon pump 10 16 
Heart failure during 53 37 0.05 
convalescence 
Ventricular fibnllation 61 38 0.01 
Pericarditis 46 19 0.0004 
Bleeding 7 53 0.0001 
Coronary angioplasty 9 59* 
Bypass surgery 16 29 
Percutaneous transluminal anglOplasty was perfonned more frequently 
in the thrombolYSIS group when the 46 patients with angioplasty imme-
diately after thrombolysis are included (*). Only p values of 0.05 or less 
are reported. 
ography was perfonned. In some of the patients with severe 
residual stenosis of the infarct-related coronary artery. per•
cutaneous transluminal coronary angioplasty was attempted 
as part of the recanalization procedure. Subsequently, ni•
troglycerin and lidocaine infusions were withdrawn. Admin•
istration of heparin was started as soon as measured recal•
cification time was less than 6 minutes. Starting in January 
1984 thrombolytic treatment was instituted immediately after 
infonned consent was obtained with injections of acetyl•
salicylic acid and prednisolone followed by 500,000 U strep•
tokinase intravenously over 10 to 20 minutes. The patient 
100 % 
80 
60 
40 
20 
t 
was then prepared for cardiac catheterization and treated as 
described earlier. 
Post-therapy procedures. Serum alpha-hydroxybutyric 
dehydrogenase enzyme detenninations were made on ad•
mission, every 12 hours during 2 days and then every 24 
hours until 5 days after admission. Cumulative release of 
alpha-hydroxybutyric dehydrogenase was calculated from 
these data as described earlier (18). In two hospitals total 
lactate dehydrogenase was measured instead and converted 
to alpha-hydroxybutyric dehydrogenase by exchange of 
standards. 
Radionuclide angiography was carried out at the bedside 
on the first, second or third day after admission and repeated 
before hospital discharge and after 3 months. Gated images 
were obtained with 20 frames in each cycle after in vivo 
labeling with 15 mCi technetium-99m. Data were analyzed 
by a fully automated computer program on a DEC-gamma 
11 or an ADAC system (19) or with an MDS or Philips 
data analysis system. 
Before hospital discharge all patients in both groups were 
offered coronary arteriography. From the left cineventric•
ulogram in the right anterior oblique projection. left ven•
tricular ejection fraction and regional wall motion were mea•
sured (15). 
Follow-up. All patients were followed up at the out•
patient clinic for at least 1 year after admission. Recurrent 
myocardial infarction, angina pectoris, cardiac failure, by•
pass surgery and coronary angioplasty as well as prescribed 
medication were recorded. In addition, survival status was 
assessed for all patients at 6 month intervals. 
Statistical analysis. Data analysis was based on the 
"intention to treat" principle. Thus, patients who refused 
early angiography were analyzed as part of the thrombolysis 
group, according to the original treatment allocation. Dif•
ferences between the two groups were tested with the chi•
square test, Student's t test or Mann-Whitney test when 
appropriate. Two-sided p values are reported. 
... th rombo I YS I S 
• controls 
Figure 2. Cumulative distributions of infarct size 
determined from serial alpha-hydroxybutyric dehy•
drogenase measurements in control patients (.-.) 
and in patients allocated to thrombolysis (A-A). 
Patients who died before completion of the meas•
urements have been included as the largest infarct 
sizes (t) as discussed in the text. The median re•
duction of infarct size after thrombolysis is 30% 
(p = 0.0001 Mann-Whitney test) . 
o+-----------~----------,_-----------~---------
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Results 
There were 533 patients entered in the study, of whom 
302 were treated before January 1984 (intracoronary throm•
bolysis) and 231 after that time (intravenous and intracor•
onary thrombolysis), Of the 533 patients, 264 were ran•
domized to the thrombolysis group and 269 to the control 
group, In Table I the number of patients in each study center 
is presented with the results of acute angiography in the 
thrombolysis group. The largest number of patients (237) 
was submitted by the Thoraxcenter, where the study was 
initiated in May 1981. The Zuiderziekenhuis, the Free Uni•
versity and the St. Annadal Hospital joined the study in 
1983, and the University of Leiden joined in 1984. 
Baseline characteristics in the two groups of patients 
(Table 2). All baseline data were distributed evenly, in•
cluding a history of previous myocardial infarction in 116 
patients (22%) and previous bypass surgery in 13 patients 
(2%). Similarly, maintenance therapy and therapy initiated 
within 24 hours preceding entry in the trial and the hemo•
dynamic state at admission were the same in both groups. 
Patients were entered in the study if they arrived within 
4 hours after the onset of symptoms. Forty-four control and 
39 thrombolysis patients were already hospitalized before 
the onset of myocardial infarction. The median time to hos•
pital admission was 90 minutes. The median time of arrival 
in the catheterization laboratory was 170 minutes, whereas 
streptokinase infusion was started 195 minutes after the 
onset of symptoms (Fig. 1). These data were similar in the 
four participating hospitals. 
Acute coronary angiography and thrombolysis. 
Thirty-five (13%) of the 269 patients allocated to throm•
bolytic treatment did not undergo coronary angiography. 
Twenty of these refused the intervention, two patients were 
resuscitated after randomization, one was later found to have 
a contraindication, one died and in six the catheter could 
not be passed through the aorta. Angiography was per•
formed in the remaining 234 patients. In 136 patients who 
underwent catheterization without previous intravenous 
streptokinase, the infarct-related vessel was occluded in 111 
(82 %) and recanalization was achieved in 88 (79%) of these 
after 30 minutes of streptokinase infusion (median). After 
intravenous streptokinase administration an occluded artery 
was found in 58 of 98 patients. Intracoronary streptokinase 
caused recanalization in 39 patients whereas in 5 patients 
the thrombus was perforated by guide wire or angioplasty 
catheter. Thus, a patent artery was ultimately achieved in 
85% of patients by combined intravenous and intracoronary 
thrombolysis. The median time from the onset of symptoms 
to angiographic documentation of patency of the infarct•
related artery was 200 minutes (range 55 to 375). There 
were no significant differences among the angiographic data 
in the four centers (Table 1). The infarct -related coronary 
artery was the left main stem in 1 patient, the left anterior 
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Figure 3. Median and 50% range (first to third quartile) of hy•
droxybutyric dehydrogenase Q72 in patients allocated to throm•
bolysis (.) or conventional treatment (e), in relation to the time 
interval between onset of symptoms and randomization. The num•
bers denote the number of patients in each time interval. 
descending artery in 102 patients, the left circumflex artery 
in 40, the right coronary artery in 89 and a bypass graft in 
2. To improve recanalization, coronary angioplasty was at•
tempted in 46 patients with severe stenosis of the infarct•
related artery after thrombolysis in whom the procedure was 
judged to be technically and organizationally feasible (3). 
In 44 patients this additional procedure was successful, while 
reocclusion of a subtotal lesion occurred after angioplasty 
in 2 patients. The severity of the lesion in the infarct-related 
vessels is presented in Table 3. 
Clinical course. Complications during the clinical course 
in the hospital are summarized in Table 4. These data in•
clude all events up to 14 days after admission, in the coro•
nary care unit, in the catheterization laboratory or in the 
medium care unit. There were no differences in reinfarction, 
angina pectoris or heart failure in the two treatment groups. 
Ventricular fibrillation occurred more frequently in the con•
trol patients, as did pericarditis, characterized by posture•
related chest pain and a friction rub, while bleeding occurred 
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Table 5. Left Ventricular Ejection Fraction on Radionuclide Angiography Before 
Hospital Discharge 
Control Group ThrombolysIs Group 
No, Ejection FractIOn No Ejection Fraction p Value 
All patients 
Days 2 to 4 200 43 ± 14 218 45 ± 14t 0,05 
Days 10 to 20 172 44± 15 189 48 ± 1St 0,003 
~ LVEF 141 0.9 ± 11 161 3.7 ± 9* 0.0001 
Intracoronary thrombolysis 
Days 2 to 4 113 41 ± 14 123 45 ± 14t 004 
Days 10 to 20 93 42 ± 14 96 48 ± 14t 0.003 
~ LVEF 78 0.6 ± 10 82 3.9 ± 8* 0.0001 
Intravenous plus intracoronary 
thrombolysis 
Days 2 to 4 87 44± 15 95 46 ± 14t NS 
Days 10 to 20 79 45 ± 16 93 48 ± 15t NS 
~ LVEF 63 1.3± 13 79 3,5 ± 11* 0,005 
First infarction 
Days 2 to 4 159 44± 14 179 47 ± 13t 0.04 
Days 10 to 20 138 46 ± IS 158 50 ± 14t 0.009 
~ LVEF 113 1.3± 12 137 3.6 ± 9* 0.0001 
Anterior infarction 
Days 2 to 4 86 34 ± 13 100 39 ± 13t 0.02 
Days 10 to 20 68 35 ± 14 89 44 ± 16t 0.0006 
~ LVEF 58 1.3 ± 9 71 4.9 ± 9* 0.0001 
Inferior infarction 
Days 2 to 4 114 49 ± 12 118 50 ± 12t NS 
Days 10 to 20 104 49 ± 12 100 52 ± 12t NS 
~ LVEF 83 0.7 ± 13 90 2.8 ± 9* 0,005 
*p Value, paired t test for difference In ejection fraction measurements; tp value, unpaired t test for 
comparison of control and thrombolysis patients. Only p values of 0.05 or less are reported. ~ LVEF = 
difference between the two measurements of ejection fraction in pal1ents in whom both measurements were 
available, LVEF = left ventricular ejection fraction; NS = not significant. In the control group the difference 
in ejection fraction measurements did not reach statistical significance in any subgroup, but ejection fraction 
improved in thrombolysis patients. 
more frequently after thrombolysis. In most cases bleeding 
was limited to the puncture site for angiography. Several 
observations related to heart failure in the acute phase were 
more frequent in control patients; this was, however, of 
borderline significance. For example, cardiogenic shock 
(p = 0.08) and treatment with dopamine and dobutamine 
(p = 0.03) occurred more frequently in control patients. 
Similarly, heart failure during reconvalescence was more 
frequent in control patients (p = 0.05). Treatment after 
hospital discharge was similar in both groups, including beta 
blockers in 101 control patients and 113 allocated to throm•
bolysis and anticoagulant agents in 80 and 79 patients, re•
spectively. 
Myocardial enzyme release. Infarct size was estimated 
from serial serum enzyme measurements during the first 72 
hours, In 317 patients alpha-hydroxybutyric dehydrogenase 
levels were obtained, while in 131 patients from two hos•
pitals total lactate dehydrogenase levels were used and con•
verted to cumulative alpha-hydroxybutyric dehydrogenase 
release. In 28 patients alpha-hydroxybutyric dehydrogenase 
was both measured directly and estimated from total lactate 
dehydrogenase levels. The regression equation between 
measured (M) and estimated (E) alpha-hydroxybutyric de•
hydrogenase was E = 0,994 X M - 3 and the standard 
error of the estimate was 334 U. Because there was no 
systematic difference between estimated and measured al•
pha-hydroxybutyric dehydrogenase release, both were com•
bined in the analysis. Data were incomplete in 30 patients 
who died within 72 hours after admission, in 17 patients 
without serum creatine kinase elevation and in 38 other 
patients. Because most patients who died within 72 hours 
had pump failure, these were entered in the analysis as 
having the largest infarcts (18). Similarly. patients without 
creatine kinase elevation, who did not develop an infarct. 
were entered as having the smallest infarcts based on alpha•
hydroxybutyric dehydrogenase levels, 
Cumulative data in Figure 2 indicate a 30% smaller 
infarct size in the treated group (p = 0.0001, Mann-Whitney 
test). This difference was also apparent when patients with 
a first infarct only (p = 0,0001), patients with anterior wall 
infarction (p = 0.005) and patients with inferior wall in•
farction (p = 0.007) were analyzed separately, Further-
JACC Vol. 7, No 4 
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more, similar results were obtained when the patients who 
died within 72 hours were not included in the analysis and 
when data from the five hospitals were analyzed separately. 
Median values for alpha-hydroxybutyric dehydrogenase in•
farct size in control and thrombolysis patients were 1,100 
and 770 U/1iter, respectively. In patients with a first infarct 
these values were 1,140 and 790 Ulliter, respectively, in 
anterior wall infarction 1,280 and 840 U/liter, respectively 
and in inferior wall infarction 970 and 670 U/liter, respec•
tively. In Figure 3 alpha-hydroxybutyric dehydrogenase re•
lease is shown in relation to the interval between the onset 
of symptoms and hospital admission. In patients allocated 
to the control group, alpha-hydroxybutyric dehydrogenase 
release was independent of the interval between the onset 
of symptoms and admission. On the other hand, we found 
smaller enzyme release in patients allocated to thrombolysis 
within 2 hours after the onset of symptoms. These data 
indicate a 51 % reduction of infarct size by thrombolysis in 
patients admitted within 1 hour, a 31 % reduction of infarct 
size in those admitted between 1 and 2 hours and a 13% 
reduction in patients admitted between 2 and 4 hours after 
the onset of symptoms. 
Left ventricular function (Table 5). Left ventricular 
ejection fraction was measured by radionuclide angiography 
between day 2 and day 4 in 418 patients and before hospital 
discharge in 361 patients. Missing data were equally dis•
tributed between the two treatment groups and were due to 
death, transfer to other hospitals, patient refusal, unavail•
ability of the gamma camera or other administrative reasons. 
There was no change in global left ventricular ejection frac•
tion between the second day and hospital discharge in the 
control group. In the thrombolysis group left ventricular 
ejection fraction before discharge was 3.7 ± 9.0% higher 
than the first measurement. Accordingly, ejection fraction 
after 10 to 20 days was approximately 4% higher when 
thrombolysis was compared with conventional treatment. 
This difference was Significant in the whole group, in pa•
tients treated with intracoronary thrombolysis only, in pa•
tients with a first infarction and in those with anterior in-
Table 6. Clinical Follow-Up 
Control Thrombolysis 
Group Group 
No. of patients 264 269 
Death 42 23 
Reinfarction 16 36 
Acute PTCA 46 
Late PTCAICABG 40 62 
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farction. Similarly, a 6% greater ejection fraction was found 
during cardiac catheterization in the thrombolysis group. 
Again these differences were similar in patients with a first 
infarct only and in patients with anterior wall or inferior 
wall infarction on admission and in both treatment protocols 
(15). 
Follow-up (Tables 6 and 7). Clinical follow-up ranged 
from 1 to 48 months after admission. There was a 45% 
reduction of mortality after thrombolysis. This was offset 
by a higher incidence of late reinfarction and more frequent 
performance of late coronary angioplasty or bypass surgery 
after thrombolysis. The reduction in mortality was present 
in all subgroups, and it was similar in all five hospitals. 
The subgroup of patients without early angiography and 
those in whom recanalization failed fared worse than those 
in whom recanalization was achieved. On the other hand, 
there was only 1 death in 65 patients with a patent infarct•
related vessel at angiography and also 1 death in 46 patients 
in Whom coronary angioplasty was performed immediately 
after thrombolysis. This particular patient underwent throm•
bolysis and angioplasty of the left anterior descending ar•
tery. Despite treatment with anticoagulant agents and ni•
fedipine, he developed postinfarction angina. After 7 days 
the artery was reoccluded at the same site and coronary 
angioplasty was repeated. After 31 days the patient devel•
oped a new anteroseptal infarction and died from intractable 
cardiogenic shock. 
Discussion 
The primary aim of the present study was the analysis 
of the effect of early thrombolysis on the clinical course 
and survival of patients with acute myocardial infarction. 
The results demonstrate that thrombolysis in the first hours 
after the onset of infarction can reduce myocardial damage 
and thus preserve part of the function of the left ventricle 
and improve patient survival. In one other randomized trial 
(20,21) there was a similar improvement in survival, al•
though left ventricular function and infarct size appeared 
No 
Thrombolysis 
Angiography* O~O .~O .~. 
35 65 133 36 
5 1 8 9 
4 9 21 3 
13 31 2 
9 18 28 7 
*Patients who were allocated to the thrombolysis group but did not undergo acute angiography. Major 
complications (mortality and nonfatal recurrent infarction) and coronary artery bypass surgery (CABG) or 
percutaneous transluminal coronary anglOplasty (PTCA) in patients allocated to conventional treatment (control) 
or thrombolysis. Symbols as in Table I. 
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Table 7. Mortality 
Control Thrombolysis No 
ThrombolysIs 
Group Group Angiography 0-.0 .-.0 .-.. 
Total mortality 42 23 5 8 9 
Intracoronary 23 17 4 6 7 
thrombolysis 
Intravenous and 19 6 2 2 
intracoronary 
thrombolysIs 
Fust infarct only 26 II 2 3 5 
Anterior wall Infarction 25 12 3 4 5 
Infenor wall InfarctIOn 17 II 2 4 4 
Thoraxcenter 20 II 4 4 3 
SI. Annadal 10 7 2 4 
Free Umversity 6 3 
ZUlderziekenhuis 6 
Leiden UniverSity 
Mortality In patients admitted before or since January 1984 and mortality data in the five participating 
hospitals. Patients allocated to thrombolytic treatment are grouped accordIng to the results of the Intervention. 
Note that similar trends are present In all subgroups. Symbol; as in Table I. 
unaltered (22), while results of several smaller randomized 
trials were inconclusive (23-28). The difference between 
the results of the present trial and those of other studies can 
be explained by differences in study design, by the shorter 
delay between the onset of symptoms and treatment and by 
its larger size. 
Study design. The study was designed to compare a 
new method of treatment (thrombolysis) with the accepted 
mode of therapy. Informed consent was asked only from 
patients allocated to angiography and thrombolysis as pro•
posed by Zelen (16). This design was chosen to prevent 
extensive discussions of the risk and potential benefits of 
acute angiography and thrombolysis in half of these criti•
cally ill patients who were eventually allocated to conven•
tional coronary care unit treatment. Data analysis was based 
on original treatment allocation. Therefore, the 35 patients 
who did not undergo acute angiography were analyzed as 
part of the thrombolysis group. This subgroup included a 
few patients in shock who refused the intervention "because 
they wanted to be left alone." This is reflected by the rel•
atively high mortality in this group (5 of 35 patients) (Table 
6). Because similar patients must be part of the control 
group, removal of this subgroup from the intervention group 
would falsely favor the effect of thrombolytic treatment. 
Yet it is evident that these deaths are not related to the 
thrombolytic therapy. 
Possible limitations. The interpretation of this study might 
be questioned because of changes in the protocol in January 
1984, the inclusion of coronary angioplasty in some of the 
patients, missing data, the lack of coronary arteriography 
on admission in the control group and the absence of direct 
measurements of baseline left ventricular function. These 
points will therefore be discussed in detail. 
Because the aim of the trial was not to study the effect 
of intracoronary streptokinase itself, but rather to study the 
effect of early reperfusion, we decided to combine both 
intravenous and intracoronary thrombolysis in the later pa•
tients when it became apparent that the preparation of the 
catheterization laboratory, the introduction of catheters and 
the first angiogram delayed the administration of strepto•
kinase by approximately I hour, while several reports (8-10) 
indicated that recanalization occurred in a considerable num•
ber of patients with administration of intravenous strepto•
kinase. 
Direct perforation of the thrombus was attempted in 5 
patients and coronary angioplasty was performed in addition 
to the streptokinase infusion in 46 patients. This intervention 
was considered an integral part of the recanalization pro•
cedure because earlier observations indicated that patients 
with residual subtotal occlusion after thrombolysis are at 
increased risk for reocclusion, which would negate the effect 
of thrombolysis (3). Coronary angioplasty was not associ•
ated with complications. In fact, alpha-hydroxybutyric de•
hydrogenase release after coronary angioplasty was de•
creased and left ventricular ejection fraction was higher than 
in patients in whom only thrombolysis was carried out (15). 
Therefore, it is likely that the beneficial effects of throm•
bolysis in the present study would have been less apparent 
without additional coronary angioplasty. 
No patients were lost to follow-up with respect to mor-
lACC Vol 7, No 4 
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tality or major clinical events, which represent the major 
end points of the study, Missing data on left ventricular 
function were due to death of the patients, patient refusal, 
transfer to other hospitals, lack of technical facilities at the 
required time or intervening bypass surgery. It is unlikely 
that this would invalidate the results because missing data 
were equally distributed between the two groups and be•
cause similar differences were observed between patients 
allocated to thrombolysis and control patients in various 
subgroups. Also, there were no differences in baseline data 
between patients with or without measurements of left ven•
tricular function. 
In contrast with other trials (20-28), early angiography 
was not performed in our control group, Therefore, the 
coronary anatomy on admission could not be studied in these 
patients. This procedure was elected because acute angi•
ography is not a part of conventional management of myo•
cardial infarction. In fact, angiography might expose these 
patients to a small but pertinent risk, which could worsen 
prognosis in the control group (13). Similarly, determination 
of left ventricular function by radionuclide angiography was 
not attempted on admission because this would have delayed 
the intervention and thus diminish the possible salutary ef•
fects of recanalization. 
Angiography in acute myocardial infarction. Earlier 
data from pilot studies performed at the Thoraxcenter (13) 
indicated that the risk of mortality, directly related to intra•
coronary infusion of streptokinase in patients with acute 
myocardial infarction, might be as high as 5%. However, 
despite 5 deaths during the catheterization procedure, 14 
day mortality in patients allocated to thrombolysis was lower 
(14 deaths [5%]) than in the control group (26 deaths [10%]). 
In our experience the risk of the intervention is not so much 
associated with early angiography itself as with the actual 
recanalization, We thus agree with DeWood et al. (29). who 
reported that early angiography can be performed without 
excessive risk in patients with myocardial infarction. The 
82% incidence of coronary occlusion at angiography and 
the 79% recanalization rate in patients treated with intra•
coronary streptokinase in the present study are consistent 
with other reports on early angiography and intracoronary 
thrombolysis (1-4,20,23-28). 
Myocardial enzyme release. Total alpha-hydroxybu•
tyric dehydrogenase release in 72 hours was calculated as 
a measure of infarct size using a two compartment model 
(30). This model takes into account the fractional catabolic 
rate or clearance of the enzymes from the blood and is 
insensitive to faster washout after reperfusion (30,31). Ear•
lier studies (32) demonstrated similar results when infarct 
size was estimated from different enzymes including crea•
tine kinase, creatine kinase-MB isoenzyme, alpha-hydroxy•
butyric dehydrogenase and aspartate aminotransferase. In 
the present study, alpha-hydroxybutyric dehydrogenase re•
lease was measured because it can be computed accurately 
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from samples taken at 12 hour intervals, whereas creatine 
kinase should be sampled more frequently. Furthermore, 
the error in the computed total enzyme release due to bio•
logic variations in the fractional catabolic rate of alpha•
hydroxybutyric dehydrogenase is smaller than for creatine 
kinase, creatine kinase-MB isoenzyme or aspartate ami•
notransferase (32). Although estimation of infarct size by 
enzyme release is controversial, earlier studies (18) dem•
onstrated a relation between total alpha-hydroxybutyric de•
hydrogenase release and the clinical sequelae of myocardial 
infarction. Furthermore, an autopsy study (33) in 84 patients 
who died of acute myocardial infarction demonstrated that 
peak levels of lactate dehydrogenase or thermostable lactate 
dehydrogenase correlated better with anatomic infarct size 
than did peak aspartate aminotransferase. Actually, the cor•
relation between thermostable lactate dehydrogenase and 
anatomic infarct size (r = 0.79) was similar to that in a 
recent study (34) comparing anatomic infarct size with peak 
creatine kinase (r = 0.79) or total creatine kinase infarct 
size (r = 0.86). Other investigators have used peak creatine 
kinase values (20,23) or peak lactate dehydrogenase mea•
surements (27), which appeared not to be reduced after 
thrombolysis. In fact, peak creatine kinase in the Western 
Washington trial (20) was 30% higher in the streptokinase 
group than in control patients. However, such peak mea•
surements are not reliable estimates of myocardial enzyme 
release because enzyme washout is faster after reperfusion. 
In the present study we observed a faster washout of alpha•
hydroxybutyric dehydrogenase, lactate dehydrogenase and 
creatine kinase after thrombolysis. 
In our study a 30% median reduction of alpha-hydroxy•
butyric dehydrogenase release was observed in the throm•
bolysis group. This supports the hypothesis that myocardial 
tissue can be salvaged by early thrombolysis. The estimation 
of alpha-hydroxybutyric dehydrogenase release from lactate 
dehydrogenase measurements in two hospitals did not affect 
the difference between the thrombolysis and control groups, 
because similar differences between these two groups were 
observed in all five hospitals. Although these methods have 
not been validated in patients after coronary reperfusion. it 
is unlikely that myocardial salvage is overestimated by com•
putation of alpha-hydroxybutyric dehydrogenase release. In 
fact. total creatine kinase release in dogs was approximately 
10% greater after reperfusion than without reperfusion at 
the same anatomic infarct size. whereas enzyme breakdown 
in the circulation was not affected by the presence of strep•
tokinase (35). If the data from such studies apply to alpha•
hydroxybutyric dehydrogenase release in patients with acute 
myocardial infarction. the actual salvage of myocardium 
would even be underestimated. The observed reduction of 
alpha-hydroxybutyric dehydrogenase release is in agreement 
with data reported by Anderson et al. (28). From their Figure 
6 we computed a 40% reduction of total lactate dehydro•
genase-I isoenzyme release in the thrombolysis group com-
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pared with conventionally treated patients. Thus both studies 
are consistent with a reduction of enzymatic infarct size 
after thrombolysis. 
Left ventricular function. Global left ventricular ejec•
tion fraction was measured by contrast angiography and 
radionuclide angiography. Both methods showed a higher 
ejection fraction 2 weeks after thrombolysis than after con•
ventional therapy (15). This improvement was seen in in•
ferior wall as well as in anterior wall infarction and applied 
to patients with a first infarct as well as to those with re•
current infarction. Some differences between the two groups 
in left ventricular ejection fraction measured by radionuclide 
angiography were already apparent after 2 to 4 days (Table 
5), although these differences were of borderline signifi•
cance. Although no measurements of ejection fraction were 
performed on admission, we may presume that these data 
were similar in both groups because other baseline data were 
also evenly distributed. The data then indicate a gradual 
recovery of left ventricular function during the first 2 weeks 
after reperfusion (36). The differences in ejection fraction 
between the two groups of patients were small (4%). How•
ever, the global left ventricular ejection fraction is related 
to the function of both the infarcted myocardium and other 
areas. Thus, changes in the infarcted area may be under•
estimated because of compensatory changes elsewhere. The 
improvement in left ventricular function after thrombolysis 
is supported by analysis of regional wall motion and by the 
smaller end-diastolic and end-systolic volumes after throm•
bolysis, measured by contrast angiography (15). 
Earlier experiments have demonstrated salvage of myo•
cardial function after early coronary reperfusion in dogs 
(37-39). In addition, several studies reported a higher ejec•
tion fraction in patients with successful thrombolysis than 
in patients whose infarct-related coronary artery remained 
occluded (40-43) or in historical control patients (44). In 
other randomized trials, only Anderson et al. (28) reported 
a beneficial effect on ejection fraction after streptokinase 
treatment. Although the lack of a beneficial effect in other 
series may be due to the small number of patients studied, 
the different results between our trial and those of two other 
larger trials (20-23) can be explained by the longer delay 
until treatment in the latter studies because it is less likely 
that recanalization after 4 or 6 hours of occlusion will sal•
vage significant amounts of myocardium in the majority of 
patients (38,39). In fact, the data from the present trial 
indicate that a marked reduction of infarct size can be achieved 
only in patients admitted within 2 hours after the onset of 
symptoms. 
Clinical course and follow-up. Survival was improved 
significantly by early thrombolysis. Furthermore, there was 
a borderline significant reduction of heart failure and shock 
in patients allocated to thrombolysis. These data are in 
agreement with the observed reduction of infarct size and 
preservation of left ventricular function. Actually, the 1 year 
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survival rates are very similar to those reported by inves•
tigators in the Western Washington Trial (21), although 
these investigators did not find differences in intermediary 
measurements, such as infarct size or left ventricular func•
tion (20). 
Unfortunately, these beneficial effects of thrombolytic 
therapy on survival were offset by a higher incidence of 
reinfarction, particularly in patients with an inferior wall 
infarction (14). Because reinfarction occurred in some of 
the patients despite adequate anticoagulant therapy or after 
successful coronary angioplasty, further studies are war•
ranted to determine the optimal mode of treatment after 
thrombolysis. Bleeding after thrombolytic treatment oc•
curred frequently at puncture sites, but did not result in 
significant morbidity (45). 
Conclusions. The aim of recanalization in patients with 
acute myocardial infarction is rapid restoration of blood flow 
to the jeopardized myocardium to preserve viable myo•
cardial cells. Ultimately this should result in preservation 
of myocardial function and improved prognosis after the 
infarction. Although the measurements of infarct size and 
left ventricular function used in this study might be criti•
cized, the consistency of the observations supports the true 
benefits of early thrombolysis in patients with myocardial 
infarction. In contrast with other studies that either were too 
small (24-27) or initiated treatment later after the onset of 
symptoms (20-23), we demonstrated a 30% smaller infarct 
size estimated from myocardial enzyme release as well as 
preservation of left ventricular function documented by con•
trast angiography and radionuclide angiography in patients 
allocated to early thrombolytic therapy, as well as a reduc•
tion of early and late mortality. Future studies should in•
vestigate whether intracoronary administration of a throm•
bolytic agent is indeed mandatory, or whether similar results 
can be obtained by intravenous infusion of newer throm•
bolytic drugs such as the tissue plasminogen activator (46-48). 
Finally, strategies should be developed for early recognition 
of the symptoms of myocardial infarction by the patient and 
for immediate intervention, because myocardial salvage is 
only attainable if myocardial blood flow is restored within 
the first few hours of infarction. 
Appendix 
Participating Centers and Collaborators 
Thoraxcenter, Erasmus University and University Hospital Dijk•
zigt, Rotterdam. Marcel J. B. M. vd Brand, MD, Pim J. de Feyter, MD, 
Paolo Fioretti, MD, Paul G. Hugenholtz, MD, Patrick W. Serruys, MD, 
Maarten L. Simoons, MD, William Wijns, MD. 
Department of Cardiology, Free University, Amsterdam. Machiel 
J. van Eenige. MSc, Jan C. J. Res, MD, Jan P. Roos, MD. Freek W. A. 
Verheugt, MD, Frans C. Visser, MD, Ernst E. vd Wall, MD. 
Department of Cardiology, Zuiderziekenhuis, Rotterdam. Dlederik 
C. A. van Hoogenhuyze. MD. X. Hanno Krauss. MD. Willem J. Remme. 
MD. 
Department of Cardiology. St. Annadal Hospital, Maastricht. Frits 
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W. H. M. Bar, MD, Simon H. J. G Braat, MD, Pedro Brugada, MD, 
Karel den Dulk, MD, Wim T Hermens, MSc, Hem J. J. Wellen" MD. 
Chns de Zwaan. MD. 
Department of Cardiology, University Hospital, Leiden. Berend 
Buis. MD. Jos Engbers. MD, Arnoud vd Laarse, PhD. 
Data processing center, Thoraxcenter, Erasmus University, Rot•
terdam. Sophie vd Does. Ron T van Domburg, MSc, Jacobu, Lubsen, 
PhD, Jan P. van Mantgem, MD, Karel J. de Neef. MD. Juan Planellas, 
MD. Frank Vermeer. MD. Anneke A Wagenaar, Inge C. J Zorn 
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